Figure 1.
Considerations for etiologies and management of cytopenias after CAR T-cell infusion. ∗Remains speculative. #Antiviral prophylaxis is initiated early after CAR-T infusion and continued for 6 to 12 months. #Anti-PJP prophylaxis is started at day ∼28 until CD4+ cell count >200/mm3. #If the ANC has not recovered to >500/mm3 by day 7 to 10, consider institution of G-CSF. ANC, absolute neutrophil count; IEC-HS, hemophagocytic lymphohistiocytosis-like hyperinflammatory syndrome associated with immune effector cells; LD, lymphodepletion; LGL, large granular lymphocytosis; NGS, next generation sequencing; TA-TMA, transplant-associated thrombotic microangiopathy; TPO, thrombopoietin.

Considerations for etiologies and management of cytopenias after CAR T-cell infusion. ∗Remains speculative. #Antiviral prophylaxis is initiated early after CAR-T infusion and continued for 6 to 12 months. #Anti-PJP prophylaxis is started at day ∼28 until CD4+ cell count >200/mm3. #If the ANC has not recovered to >500/mm3 by day 7 to 10, consider institution of G-CSF. ANC, absolute neutrophil count; IEC-HS, hemophagocytic lymphohistiocytosis-like hyperinflammatory syndrome associated with immune effector cells; LD, lymphodepletion; LGL, large granular lymphocytosis; NGS, next generation sequencing; TA-TMA, transplant-associated thrombotic microangiopathy; TPO, thrombopoietin.

Close Modal

or Create an Account

Close Modal
Close Modal